Cargando…

Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution

The success of targeted cancer therapy is limited by drug resistance that can result from tumor genetic heterogeneity. The current approach to address resistance typically involves initiating a new treatment after clinical/radiographic disease progression, ultimately resulting in futility in most pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonsson, Vanessa D., Blakely, Collin M., Lin, Luping, Asthana, Saurabh, Matni, Nikolai, Olivas, Victor, Pazarentzos, Evangelos, Gubens, Matthew A., Bastian, Boris C., Taylor, Barry S., Doyle, John C., Bivona, Trever G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347024/
https://www.ncbi.nlm.nih.gov/pubmed/28287179
http://dx.doi.org/10.1038/srep44206
_version_ 1782513991436730368
author Jonsson, Vanessa D.
Blakely, Collin M.
Lin, Luping
Asthana, Saurabh
Matni, Nikolai
Olivas, Victor
Pazarentzos, Evangelos
Gubens, Matthew A.
Bastian, Boris C.
Taylor, Barry S.
Doyle, John C.
Bivona, Trever G.
author_facet Jonsson, Vanessa D.
Blakely, Collin M.
Lin, Luping
Asthana, Saurabh
Matni, Nikolai
Olivas, Victor
Pazarentzos, Evangelos
Gubens, Matthew A.
Bastian, Boris C.
Taylor, Barry S.
Doyle, John C.
Bivona, Trever G.
author_sort Jonsson, Vanessa D.
collection PubMed
description The success of targeted cancer therapy is limited by drug resistance that can result from tumor genetic heterogeneity. The current approach to address resistance typically involves initiating a new treatment after clinical/radiographic disease progression, ultimately resulting in futility in most patients. Towards a potential alternative solution, we developed a novel computational framework that uses human cancer profiling data to systematically identify dynamic, pre-emptive, and sometimes non-intuitive treatment strategies that can better control tumors in real-time. By studying lung adenocarcinoma clinical specimens and preclinical models, our computational analyses revealed that the best anti-cancer strategies addressed existing resistant subpopulations as they emerged dynamically during treatment. In some cases, the best computed treatment strategy used unconventional therapy switching while the bulk tumor was responding, a prediction we confirmed in vitro. The new framework presented here could guide the principled implementation of dynamic molecular monitoring and treatment strategies to improve cancer control.
format Online
Article
Text
id pubmed-5347024
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53470242017-03-14 Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution Jonsson, Vanessa D. Blakely, Collin M. Lin, Luping Asthana, Saurabh Matni, Nikolai Olivas, Victor Pazarentzos, Evangelos Gubens, Matthew A. Bastian, Boris C. Taylor, Barry S. Doyle, John C. Bivona, Trever G. Sci Rep Article The success of targeted cancer therapy is limited by drug resistance that can result from tumor genetic heterogeneity. The current approach to address resistance typically involves initiating a new treatment after clinical/radiographic disease progression, ultimately resulting in futility in most patients. Towards a potential alternative solution, we developed a novel computational framework that uses human cancer profiling data to systematically identify dynamic, pre-emptive, and sometimes non-intuitive treatment strategies that can better control tumors in real-time. By studying lung adenocarcinoma clinical specimens and preclinical models, our computational analyses revealed that the best anti-cancer strategies addressed existing resistant subpopulations as they emerged dynamically during treatment. In some cases, the best computed treatment strategy used unconventional therapy switching while the bulk tumor was responding, a prediction we confirmed in vitro. The new framework presented here could guide the principled implementation of dynamic molecular monitoring and treatment strategies to improve cancer control. Nature Publishing Group 2017-03-13 /pmc/articles/PMC5347024/ /pubmed/28287179 http://dx.doi.org/10.1038/srep44206 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Jonsson, Vanessa D.
Blakely, Collin M.
Lin, Luping
Asthana, Saurabh
Matni, Nikolai
Olivas, Victor
Pazarentzos, Evangelos
Gubens, Matthew A.
Bastian, Boris C.
Taylor, Barry S.
Doyle, John C.
Bivona, Trever G.
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
title Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
title_full Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
title_fullStr Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
title_full_unstemmed Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
title_short Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
title_sort novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347024/
https://www.ncbi.nlm.nih.gov/pubmed/28287179
http://dx.doi.org/10.1038/srep44206
work_keys_str_mv AT jonssonvanessad novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT blakelycollinm novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT linluping novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT asthanasaurabh novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT matninikolai novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT olivasvictor novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT pazarentzosevangelos novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT gubensmatthewa novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT bastianborisc novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT taylorbarrys novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT doylejohnc novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution
AT bivonatreverg novelcomputationalmethodforpredictingpolytherapyswitchingstrategiestoovercometumorheterogeneityandevolution